Here, we investigated metabolic changes in estrogen receptor‐positive breast cancer (MCF‐7) cells treated with estradiol (E2) and/or SFN to identify key metabolite panels that might provide new insights into the underlying mechanisms of the antitumor effects of SFN. This evidence concerns the gene ESR1 and breast carcinoma.